Learn more about Elia Stupka

Author Bio

Elia Stupka

Elia Stupka leads the Life Sciences group at Health Catalyst as well as contributing to overall vision and growth for the company. He is a visionary leader in digital health with a passion for innovation in health and life sciences and 20 years of experience across industry, academic and clinical settings. In his role leading data science at Dana-Farber Cancer Institute, one of the world's leading cancer organizations, Dr. Stupka brought together research, clinical and operational data to improve patient outcomes and facilitated the discovery of new treatments. He started his career as a member of the first team that annotated the human genome in Cambridge, U.K. He then worked with Nobel Laureate Sydney Brenner to build the first genome research group in Singapore. Dr. Stupka has worked at several key European research organizations such as the Telethon Institute of Genetics and University College London. He then co-directed a genomics research center at San Raffaele Hospital in Milan, Italy, where he contributed to the successful development and completion of the first commercially viable gene therapy clinical trials in Europe. He worked several years in the pharma industry, at Boehringer Ingelheim Pharma, where he headed computational biology and genomics. Over his career Dr. Stupka has published 100+ peer reviewed articles, and been cited 35,000+ times across the fields of drug development, data science and ethics. His work has contributed to the understanding of the human genome and transcriptome, the diagnosis of rare disease patients, the development of gene therapy and novel drugs on the market and the development of ethics frameworks pertaining to the fast-changing world of big data in health and biology.

Read articles by Elia Stupka


Elia Stupka

Extended Real-World Data: The Life Science Industry’s Number One Asset

The life science industry has historically relied on sanitized clinical trials and commoditized data sources (largely claims) to inform its drug development process—an under-substantiated approach that didn’t reflect how a new drug would affect broader patient populations. In an effort to gain more accurate insight into the patient experience and bring drugs to market more efficiently and safely, the industry is now expanding into extended real-world data (RWD).
To access the needed breadth and depth of patient-centric data, life science companies must partner with a healthcare transformation company that has three key qualities:

A broad and deep data asset.
Extensive provider partnerships.
An outcomes-improvement engine to support the next generation of drug development.

Read more
My Folder